Table 1 Baseline characteristics of ahDM and nonDM patients

 Age, y

76 (62–85)

76 (60–84)

72 (61.5–82.5)

0.818

 Sex, male

38 (64.4%)

19 (63.3)

18 (72)

0.571

 Atrial fibrillation

30 (54.5%)

16 (53.3)

14 (56)

0.99

 Hypertension

40 (72.7%)

21 (70)

19 (76)

0.763

 Dyslipidemia

31 (56.4%)

20 (66.6)

11 (44)

0.11

 Stroke or TIA history

24 (43.6%)

13 (43.3)

11 (44)

0.99

 Smoking history

30 (54.5%)

15 (50)

15 (60)

0.588

 Coronary artery disease

25 (45.5%)

16 (53.3)

9 (36)

0.278

 NIHSS

15 (9–20)

17 (9–24)

12 (6.5–16)

0.015

 Serum glucose

8.2 (5.6–13.3)

12.9 (9.6–16.15)

5.5 (5.2–6.6)

< 0.001

 Anticoagulant use

9 (16.4%)

5 (16.7)

4 (16)

0.99

 Antiplatelet use

29 (52.7%)

16 (53.3)

13 (52)

0.99

 APTT (s)

33.01 ± 4.54

32.64 ± 4.63

33.4 ± 4.41

0.541

 PT (s)

11.2 (10.68–12)

11.1 (10.48–11.38)

11.4 (10.8–12.2)

0.209

 Fibrinogen (g/L)

3.13 (2.58–3.49)

3.08 (2.57–3.55)

3.15 (2.71–3.45)

0.615

 INR

0.97 (0.93–1.04)

0.97 (0.91–1.0)

0.99 (0.94–1.06)

0.234

 D-dimer (ng/mL)

239.5 (153.8–621.5)

231 (161.8–519.8)

369 (137.0–653.5)

0.227

Stroke etiology

0.94

 CE

34 (61.8)

18 (60)

16 (64)

 LAA

15 (27.2)

8 (26.6)

7 (28)

 Other determined

3 (5.45)

2 (6.7)

1 (4)

 Cryptogenic

3 (5.45)

2 (6.7)

1 (4)

Thrombus location

0.623

 ICA

18 (32.7)

10 (33.3)

8 (26.6)

 M1

18 (32.7)

8 (26.2)

10 (33.3)

 M2

9 (16.3)

5 (16.7)

4 (16)

 ACA

2 (3.6)

2 (6.6)

0 (0)

 BA

8 (14.5)

5 (16.6)

3 (12)